GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US Neurosurgical Holding Inc (OTCPK:USNU) » Definitions » Cash Flow from Operations

US Neurosurgical Holding (US Neurosurgical Holding) Cash Flow from Operations : $-1.22 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is US Neurosurgical Holding Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2024, US Neurosurgical Holding's Net Income From Continuing Operations was $-0.31 Mil. Its Depreciation, Depletion and Amortization was $0.01 Mil. Its Change In Working Capital was $-0.15 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.00 Mil. And its Cash Flow from Others was $-0.00 Mil. In all, US Neurosurgical Holding's Cash Flow from Operations for the three months ended in Mar. 2024 was $-0.46 Mil.


US Neurosurgical Holding Cash Flow from Operations Historical Data

The historical data trend for US Neurosurgical Holding's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Neurosurgical Holding Cash Flow from Operations Chart

US Neurosurgical Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.55 1.12 0.17 -1.41 -0.89

US Neurosurgical Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 -0.31 -0.13 -0.32 -0.46

US Neurosurgical Holding Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

US Neurosurgical Holding's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

US Neurosurgical Holding's Cash Flow from Operations for the quarter that ended in Mar. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


US Neurosurgical Holding  (OTCPK:USNU) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

US Neurosurgical Holding's net income from continuing operations for the three months ended in Mar. 2024 was $-0.31 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

US Neurosurgical Holding's depreciation, depletion and amortization for the three months ended in Mar. 2024 was $0.01 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

US Neurosurgical Holding's change in working capital for the three months ended in Mar. 2024 was $-0.15 Mil. It means US Neurosurgical Holding's working capital declined by $0.15 Mil from Dec. 2023 to Mar. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

US Neurosurgical Holding's cash flow from deferred tax for the three months ended in Mar. 2024 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

US Neurosurgical Holding's cash from discontinued operating Activities for the three months ended in Mar. 2024 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

US Neurosurgical Holding's asset impairment charge for the three months ended in Mar. 2024 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

US Neurosurgical Holding's stock based compensation for the three months ended in Mar. 2024 was $0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

US Neurosurgical Holding's cash flow from others for the three months ended in Mar. 2024 was $-0.00 Mil.


US Neurosurgical Holding Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of US Neurosurgical Holding's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


US Neurosurgical Holding (US Neurosurgical Holding) Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 325, Rockville, MD, USA, 20850
US Neurosurgical Holding Inc operates as a holding company in United State. It is a medical services company that partners with hospitals and physicians to operate facilities utilizing artistic and inventive technologies in medical treatment and diagnosis. It is engaged in providing medical treatment and diagnosis services that include stereotactic radiosurgery centers, utilizing gamma knife technology, and holds interests in radiological treatment facilities. The company is focusing on establishing cancer centers using intensity-modulated radiation therapy. Its gamma knife is a stereotactic radiosurgical device used to treat brain tumors and other malformations of the brain without invasive surgery.
Executives
Lawrence William St director 23 ASHLAND STREET, NEWBURYPORT MA 01950-1905
William F. Leimkuhler director 43 SALEM STRAITS RD, DARIEN CT 06820
Merriman Charles H Iii director
Alan Gold director, 10 percent owner, officer: President & Chairman 2400 RESEARCH BLVD, SUITE 325, ROCKVILLE MD 20850
Stanley S Shuman 10 percent owner C/O RIPPLEWOOD HOLDINGS LLC, ONE ROCKERFELLER PLAZA, NEW YORK NY 10020
Allen & Co Inc 10 percent owner 711 FIFTH AVENUE, NEW YORK NY 10022

US Neurosurgical Holding (US Neurosurgical Holding) Headlines

No Headlines